Synta's Interim GALAXY Data Encouraging Despite Stock Fall
By Catherine Shaffer
Staff Writer
Staff Writer
Wednesday, August 8, 2012
Positive interim results from its GALAXY trial of ganetespib and docetaxel for non-small-cell lung cancer (NSCLC) ran Synta Pharmaceuticals Corp.'s stock price off a cliff Thursday.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
For Sales Inquiries,
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.